Role of β-adrenergic signaling in the development of Porphyromonas gingivalis lipopolysaccharide-induced cardiac dysfunction in mice Authors: Ichiro Matsuo, Kenji Suita, Yoshiki Ohnuki, Misao Ishikawa, Aiko Ito, Mariko Abe, Takao Mitsubayashi, Yasumasa Mototani, Ren Matsubara, Megumi Nariyama, Takako Nomura, Yoshio Hayakawa, Daichi Chikazu, Akira Matsuo, Satoshi Okumura Published: 2026 ABSTRACT AbstractThe aims of the present study were to investigate the changes of cardiac dysfunction induced by Porphyromonas gingivalis lipopolysaccharide (PG-LPS, 0.8 mg/kg/day for a week) in mice, and to elucidate the underlying mechanisms, as well as to evaluate the effect of the non-selective β-blocker propranolol (PPL) on the PG-LPS-induced changes. Since little is known about the involvement of the sympathetic nervous system in the development or exacerbation of periodontitis-induced cardiovascular disease (CVD), we first examined the effects of PG-LPS on heart variability. The normalized low frequency, an index of sympathetic nervous activity, was significantly increased after administration of PG-LPS, with an increase of mean heart rate at all time points examined. We then evaluated the effects of PPL on these PG-LPS-induced changes. Left ventricular ejection fraction was significantly decreased from baseline (from 66 ± 1.1 to 57 ± 2.3%) by PG-LPS, while PPL ameliorated the dysfunction. PG-LPS significantly increased cardiac fibrosis (approximately 3.1-fold), myocyte apoptosis (approximately 5.1-fold) and oxidative DNA damage (approximately sixfold), and PPL blocked these changes. Mechanistic studies suggested that impairment of cardiac function in PG-LPS-treated mice involves activation of NADPH oxidase 4/receptor-interacting protein 3/calmodulin kinase II signaling, leading to Ca2+ leakage from sarcoplasmic reticulum mediated by phosphorylation of phospholamban and ryanodine receptor 2. Overall, our results suggested that activation of β-adrenergic signaling might play an important role in the development of periodontitis-induced CVD.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-57762-1.Keywords: Cyclic AMP, Signal transduction, Apoptosis, Fibrosis, Periodontitis, Heart failureSubject terms: Cardiology, Cell biology, Diseases, Medical research, Physiology Introduction Periodontal disease (PD) is a multifactorial disease associated with the destruction of the supporting structures of the teeth, such as the alveolar bones, periodontal ligaments and cementum, leading to tooth loss 1. This inflammatory disease represents a major public health problem and the prevalence of severe PD has been estimated to amount to 9.8% of the global population (about 0.8 billion people) 2. Previous studies have found a relationship between PD and the sympathetic nervous system (SNS). A cross-sectional study of 1,426 subjects between the age of 25 and 74 years in Erie County, New York, indicated that psychosocial factors related to stressful life event, leading to SNS activation, are risk factors for severe periodontitis 3. Furthermore, Martin et al. reported that activation of β-adrenergic receptor (β-AR) signaling with a non-selective agonist, isoproterenol, increased the lingual alveolar bone loss in experimental PD in rats 4. Moreover, treatment of experimental PD in rats with non-selective β-AR blocker, propranolol (PPL), inhibited Porphyromonas gingivalis (PG)-induced alveolar bone loss 4–6. Psychological stress alters sympathetic signaling and might contribute to the onset and progression of PD through activation of the hypothalamic–pituitary–adrenal (HPA) axis with the subsequent release of cortisol 7 and activation of the sympathetic-adrenal-medullary (SAM) system with the subsequent release of epinephrine and norepinephrine 8,9. Activation of the SAM system is clinically associated with elevated blood pressure, increased heart rate, and altered rheological parameters. These responses can be influenced by systemic factors such as obesity and are associated with PD 10. Recent studies have confirmed that the harmful effects of PD are not restricted to the oral cavity, but can also affect the overall health of subjects 11. A growing body of epidemiological evidence supports the idea that periodontal inflammation is associated with cardiovascular disease (CVD), including heart failure, atrial fibrillation and myocardial infarction 12–15. There are conflicting reports on the pro-inflammatory effects of PG-LPS. For example, systemic administration of E.Coli LPS stimulates tumor necrosis factor-α (TNF-α) production in mice, whereas PG-LPS has only a minimal stimulatory effect 16. Moreover, PG-LPS weakly activates macrophage, compared to E.Coli LPS 17,18. On the other hand, PG-LPS and E.Coli LPS similarly induce interleukin-6 production in human gingival fibroblast. Therefore, we previously examined the effects of chronic PG-LPS infusion at the concentration used in this study (0.8 mg/kg/day) on cardiac dysfunction and serum levels of IL-6, IL-1β, IL-10, IL-17, IFN-γ, MCP-1 and TNF-α, in addition to endothelial biomarkers PDGF-BB and VEGF. However, levels of various serum proinflammatory cytokines in PG-LPS-treated mice were similar to those in control mice. Cardiac function was significantly decreased in mice treated with PG-LPS with the activation of signaling such as cyclicAMP/protein kinase A and cyclicAMP/camodulin kinase II 19. In addition, pharmacological inhibition of toll-like receptor 4 (TLR4) with a TLR4 antagonist (TAK-242), attenuated the changes in cardiac function in PG-LPS-treated mice 20. We hypothesized that PG-LPS-mediated cardiac dysfunction might be mediated through the activation of β-adrenergic receptor signaling and its downstream signaling with TLR4 activation, rather than simply being a consequence of inflammation. Therefore, the aims of this study were to evaluate cardiac dysfunction in mice treated with LPS derived from PG at a dose equivalent to the circulating levels in PD patients and to clarify the mechanisms of the cardiac changes (Fig. 1A). Furthermore, to test the hypothesis that a non-selective β-blocker might inhibit not only alveolar bone loss, but also the development of systemic disease, we also examined the effects of PPL on the PG-LPS-induced changes of cardiac function. Experimental procedure and effects of PG-LPS on body weight and cardiac muscle mass. (A) Experimental protocol. Male 12-week-old C57BL/6 mice were divided into four groups, normal control group (C), PG-LPS-treated group (L), a propranolol-treated group (P), and PG-LPS plus PPL (L + P) group, and various parameters of cardiac function were evaluated. (B) Consumed amounts of food and water were similar among all four groups during the experimental period. NS, not significantly different from the Control (P > 0.05) by ANOVA/Tukey–Kramer. (C) All groups showed similar body weight changes at 1 week after PG-LPS infusion. P = NS, not significantly different from the Control (P > 0.05) by ANOVA/Tukey–Kramer. (D) All groups showed similar values of cardiac muscle (CM) weight per body weight ratio at 1 week after PG-LPS infusion, NS, not significantly different from the Control (P > 0.05) by ANOVA/Tukey–Kramer. Data are presented as means ± SD and open circles show individual data. Results Effects of PG-LPS with/without PPL treatment on food and water consumption The amounts of both food and water consumed were similar among the four groups examined (food: PG-LPS [L; n = 5]: 7.6 ± 4.0, PPL [P; n = 5]: 7.8 ± 6.5, PG-LPS + PPL [L + P; n = 5]: 7.6 ± 4.2 g/day, with no significant differences [NS; P > 0.05] vs. Control [C; n = 5]: 7.6 ± 5.0 mL/day using one-way ANOVA followed by the Tukey–Kramer post hoc test (hereafter abbreviated as ANOVA/Tukey–Kramer), water: L [n = 5]: 3.8 ± 1.4, P [n = 5]: 3.1 ± 2.2, L + P [n = 5]: 4.1 ± 2.5 ml/day, all not significantly different [all NS; P > 0.05] vs. C group [n = 5]: 3.9 ± 1.3 g/day using ANOVA/Tukey–Kramer) (Fig. 1B). Effects of PG-LPS with/without PPL treatment on body weight and heart size We monitored the body weight (BW) of the four groups at 1 week after PG-LPS treatment. The Control, PG-LPS, PPL, PG-LPS + PPL groups all showed similar BW at 1 week after the PG-LPS infusion (PG-LPS [n = 5]: 26.6 ± 0.3 g, PPL [n = 5]: 27.3 ± 0.7 g, PG-LPS [n = 5]: 27.3 ± 0.7 g, all NS [P > 0.05] vs. Control [n = 5]; 27.5 ± 0.4 g using ANOVA/Tukey–Kramer) (Fig. 1C). We also examined the effects of PG-LPS with/without PPL on heart size in terms of the ratio of cardiac muscle mass (CM) to BW (Fig. 1D). There was no difference among the four groups. These data, together with the data shown in Fig. 1B, suggest that chronic PG-LPS treatment with or without PPL at the dose used in this study did not influence food consumption, water consumption, BW or cardiac hypertrophy during the experimental period. Effects of PG-LPS with/without PPL treatment on cardiac function We conducted echocardiography to evaluate cardiac function in terms of left ventricular ejection fraction (LVEF) and fractional shortening (%FS) (Table 1). Both parameters were significantly decreased in the PG-LPS group, compared to the control (LVEF: Control [n = 5] vs. PG-LPS [n = 5]: 66 ± 1.1 vs. 57 ± 2.3%, P < 0.05 by ANOVA/ Tukey–Kramer; %FS: Control [n = 5] vs. PG-LPS [n = 5]: 31 ± 0.8 vs. 25 ± 1.1%, P < 0.01 by ANOVA/Tukey–Kramer). Importantly, PG-LPS-mediated cardiac dysfunction was significantly attenuated by pharmacological inhibition of β-AR with PPL (LVEF: PG-LPS [n = 5] vs. PG-LPS + PPL [n = 5]; 57 ± 2.3 vs. 62 ± 1.4%, P < 0.01 by ANOVA/Tukey–Kramer; %FS: PG-LPS [n = 5] vs. PG-LPS + PPL [n = 5]; 25 ± 1.1 vs. 29 ± 0.9%, P < 0.05 by ANOVA/Tukey–Kramer). Table 1Cardiac function assessed by echocardiography.CLPL + Pn = 5n = 5n = 5n = 5IVSTd0.62 ± 0.050.55 ± 0.04*0.56 ± 0.060.54 ± 0.02LVSTs0.88 ± 0.770.73 ± 0.10*0.78 ± 0.060.81 ± 0.02EDV0.20 ± 0.020.18 ± 0.020.17 ± 0.020.17 ± 0.02LVIDd4.28 ± 0.184.18 ± 0.194.06 ± 0.154.06 ± 0.15LVIDs2.96 ± 0.133.12 ± 0.14**2.93 ± 0.142.90 ± 0.14##ESV0.07 ± 0.010.08 ± 0.010.07 ± 0.010.06 ± 0.01#LVEF66 ± 1.157 ± 2.3**61 ± 1.862 ± 1.4##LVPWTd0.58 ± 0.050.54 ± 0.040.54 ± 0.050.53 ± 0.03LVPWTs0.82 ± 0.070.77 ± 0.080.74 ± 0.060.73 ± 0.07SV0.13 ± 0.010.10 ± 0.010.10 ± 0.010.10 ± 0.01%FS31 ± 0.825 ± 1.1**28 ± 1.129 ± 0.9##C: Normal control group; L: PG-LPS-trested group; P: propranolol-treated group L + P: PG-LPS plus propranolol-treated group.IVSTd (mm): Interventricular septum thickness at end-diastole.LVSTs (mm): Interventricular septum thickness at end-systole.EDV (mL): Left ventricular end-diastolic volume.LVIDd (mm): Left ventricular internal dimension at end-diastole.LVIDs (mm): Left ventricular internal dimension at end-diastole.ESV (mL): Left ventricular end-systolic volume.LVEF (%): Left ventricular ejection fraction.LVPWTd (mm): Left ventricular posterior wall thickness at end-diastole.LVPWTs (mm): Left ventricular posterior wall thickness at end-diastole.SV (mL): stroke volume.%FS: Fractional shortening.**P < 0.01 vs. Control *P < 0.05 vs. Control.##P < 0.01 vs. LPS #P < 0.05vs. LPS. Cardiac function assessed by echocardiography. C: Normal control group; L: PG-LPS-trested group; P: propranolol-treated group L + P: PG-LPS plus propranolol-treated group. IVSTd (mm): Interventricular septum thickness at end-diastole. LVSTs (mm): Interventricular septum thickness at end-systole. EDV (mL): Left ventricular end-diastolic volume. LVIDd (mm): Left ventricular internal dimension at end-diastole. LVIDs (mm): Left ventricular internal dimension at end-diastole. ESV (mL): Left ventricular end-systolic volume. LVEF (%): Left ventricular ejection fraction. LVPWTd (mm): Left ventricular posterior wall thickness at end-diastole. LVPWTs (mm): Left ventricular posterior wall thickness at end-diastole. SV (mL): stroke volume. %FS: Fractional shortening. **P < 0.01 vs. Control *P < 0.05 vs. Control. ##P < 0.01 vs. LPS #P < 0.05vs. LPS. In addition, left ventricular internal dimensions at end-systole (LVIDs), a useful predictor of systolic dysfunction 21, were significantly increased in the PG-LPS group, compared to the control (Control [n = 5] vs. PG-LPS [n = 5]: 2.96 ± 0.13 vs. 3.12 ± 0.14 mm, P < 0.01 by ANOVA/ Tukey–Kramer) and were also significantly decreased by PPL (PG-LPS [n = 5] vs. PG-LPS + PPL [n = 5]; 3.12 ± 0.14 vs. 2.90 ± 0.14 mm, P < 0.01 by ANOVA/Tukey–Kramer). These data indicate that PG-LPS treatment under the conditions used in this study induces cardiac dysfunction, at least in part, through the activation of β-AR. Effects of PG-LPS on nLF, nHF and LF/HF To evaluate changes in autonomic nervous activity, we carried out heart rate variability (HRV) analysis. We first compared the normalized LF (nLF), which may represent sympathetic activity (Fig. 2B), and the normalized HF (nHF), which may represents parasympathetic activity (Fig. 2C), at 1 day before (baseline) and 1, 3 and 7 days after PG-LPS treatment (Supplementary Fig. 1) 22. After PG-LPS, nLF was significantly increased and nHF was significantly decreased from baseline at all time points after PG-LPS administration (P < 0.01 by repeated-measures ANOVA/Bonferroni). Furthermore, the ratio of LF to EF (LV/EF), which may be an index of sympatho-vagal balance, was significantly increased from baseline at all time points after PG-LPS administration (P < 0.01 by repeated-measures ANOVA/Bonferroni) (Fig. 2D). Effects of PG-LPS on LF/HF, nHF, mean HR and SDNN. (A) Experimental timeline. ECG was recorded for 24 h at 1 day before the PG-LPS treatment (Baseline) and at 1, 3 and 7 days after the PG-LPS treatment. (B) nLF, an index of sympathetic nervous activity, was significantly greater at all time points in the PG-LPS group, compared to the baseline. **P < 0.01 (Baseline vs. PG-LPS + 1 day; Baseline vs. PG-LPS + 3 days; Baseline vs. PG-LPS + 7 days) by one-way repeated-measures analysis of variance (ANOVA)/Bonferroni post hoc test. (C) nHF, an index of parasympathetic nervous activity, was significantly smaller at all time points in the PG-LPS group, compared to the baseline. **P < 0.01 (Baseline vs. PG-LPS + 1 day; Baseline vs. PG-LPS + 3 days; Baseline vs. PG-LPS + 7 days) by one-way repeated-measures analysis of variance (ANOVA)/Bonferroni post hoc test. (D) LF/HF, an index of sympatho-vagal balance, was significantly smaller at all time points in the PG-LPS group, compared to the baseline. **P < 0.01 (Baseline vs. PG-LPS + 1 day; Baseline vs. PG-LPS + 3 days; Baseline vs. PG-LPS + 7 days) by one-way repeated-measures analysis of variance (ANOVA)/Bonferroni post hoc test. (E) Mean HR was significantly greater at all time points in the PG-LPS group, compared to the baseline. *P < 0.05 (Baseline vs. PG-LPS + 1 day; Baseline vs. PG-LPS + 7 days) or **P < 0.01 (Baseline vs. PG-LPS + 3 days) by one-way repeated-measures analysis of variance (ANOVA)/Bonferroni post hoc test. (F) SDNN, which is a measure of total autonomic instability, was significantly smaller at all time points in the PG-LPS group, compared to the baseline. **P < 0.01 (Baseline vs. PG-LPS + 1 day) or *P < 0.05 (Baseline vs. PG-LPS + 3 days; Baseline vs. PG-LPS + 7 days) by one-way repeated-measures analysis of variance (ANOVA)/Bonferroni post hoc test. Data are presented as means ± SD and open circles show individual data. These data suggest that the PG-LPS administration might activate the sympathetic nervous system. Effects of PG-LPS on mean HR To evaluate changes of heart rate (HR), we examined the mean HR at 1, 3 and 7 days after PG-LPS, compared to the baseline (Fig. 2E). Mean HR was significantly increased from baseline at all time points after PG-LPS (P < 0.05 or P < 0.01 by repeated-measures ANOVA/Bonferroni). These data, together with the HRV results, suggest that chronic PG-LPS at the physiologically realistic dose level used in this study might increase mean HR at least in part via sympathetic nerve overactivation. Effects of PG-LPS on SDNN Because the above findings indicated alterations in cardiac autonomic control by PG-LPS, we examined the standard deviation of normal R-R interval (SDNN), which is a measure of total autonomic instability (Fig. 2F)23. SDNN was significantly decreased at all time points after PG-LPS, compared to the baseline (P < 0.05 or P < 0.01 by repeated-measures ANOVA/Bonferroni), suggesting that autonomic control of the HR was altered by PG-LPS under the conditions used in this study. Effects of PG-LPS on time course changes in HR during 48 h Time course changes in HR during daytime (8:00 AM to 8:00 PM) and nighttime (8:00 PM to 8:00 AM) were examined for 48 h at 1 day before (baseline; PG-LPS-1 day) and 7 days (PG-LPS + 7 days) after PG-LPS (P < 0.01 by paired Student t-test [Baseline vs. PG-LPS + 7 days]) (Fig. 3A). Effects of PG-LPS on time course of changes in HR and changes of mean HR at nighttime versus daytime. (A) Time course of changes in HR during daytime (8:00 AM to 8:00 PM) and nighttime (8:00 PM to 8:00 AM) for 48 h determined by ECG measurement at 1 day before (baseline; PG-LPS -1 day) and 7 days (LPS 7d; PG-LPS + 7 days) after PG-LPS treatment. **P < 0.01 by paired Student t-test (Baseline vs. LPS 7d). (B) Comparison of difference in HR (delta HR) between daytime and nighttime at 1 day before the PG-LPS treatment (baseline) and at 7 days after PG-LPS treatment (LPS 7d). **P < 0.01 by unpaired Student t-test. (C) Plasma chromogranin A levels at 7 days after PG-LPS treatment (L) was significantly greater than that in the control (C). **P < 0.01 by unpaired Student t-test. (D) TH phosphorylation at Ser-40 in the heart at 7 days after PG-LPS treatment (L) was significantly greater than that in the control. **P < 0.01 by unpaired Student t-test. Data are presented as means ± SD and open circles show individual data. We also examined the difference of HR (delta HR) between daytime and nighttime at baseline and at 7 days after PG-LPS treatment, and found that the magnitude of the increase was much greater at baseline, compared to that at 7 days after PG-LPS (P < 0.01 by unpaired Student t-test) (Fig. 3B). These data suggest that circadian rhythm of HR was diminished by PG-LPS. Effects of PG-LPS on plasma chromogranin A Chromogranin A is coreleased with catecholamines by exocytosis from vesicles in the sympathetic nerve endings and adrenal medulla, and measurement of plasma chromogranin A is a useful probe of exocytotic sympathoadrenal activity 24,25. We thus examined the plasma chromogranin A levels at 7 days after PG-LPS treatment and found that the plasma chromogranin A level in PG-LPS-treated mice was significantly greater than that in the control (Control [n = 6] vs. PG-LPS [n = 6]: 419 ± 99 vs. 644 ± 126 ng/mL, P < 0.01 by unpaired Student t-test), indicating that exocytotic sympathoadrenal activity was significantly increased at 7 days after PG-LPS treatment (Fig. 3C). Effects of PG-LPS on tyrosine hydroxylase phosphorylation Norepinephrine synthesis is mediated by tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis that converts tyrosine to 3, 4-dihydroxyphenylalanine (DOPA) 26, and TH is activated by phosphorylation. Therefore, the phosphorylation level of TH is considered to be another parameter of sympathetic nervous activity, and measurement of changes in TH phosphorylation might provide further evidence in support of increased sympathetic activity. We thus examined the effects of chronic PG-LPS on TH phosphorylation at Ser-40 (Fig. 3D) in the heart and found that it was significantly greater than that in the control (Control [n = 6] vs. PG-LPS [n = 6]: 100 ± 15 vs. 143 ± 29%, P < 0.01 by unpaired Student t-test) at 7 days after PG-LPS treatment. Effects of PG-LPS with/without PPL treatment on cardiac fibrosis We next examined cardiac remodeling, which we evaluated in terms of fibrosis and myocyte apoptosis, because these changes might lead to progressive heart failure 27,28. We first assessed cardiac fibrosis by means of Masson-trichrome staining (Fig. 4A). Chronic PG-LPS infusion significantly increased the area of fibrosis, compared to the control (Control [n = 5] vs. PG-LPS [n = 5]: 0.7 ± 0.3 vs. 2.2 ± 0.6%, P < 0.01 by ANOVA/Tukey–Kramer). PPL alone did not alter the area of fibrosis. However, the PG-LPS-mediated increase of cardiac fibrosis was significantly attenuated by PPL (PG-LPS [n = 5] vs. PG-LPS + PPL [n = 5], 2.2 ± 0.6 vs. 0.7 ± 0.2%, P < 0.01 by ANOVA/Tukey–Kramer) (Fig. 4B). Effects of PPL on PG-LPS-induced heart fibrosis and cardiac myocyte apoptosis. (A) Representative images of Masson-trichrome-stained sections of cardiac muscle in the Control (C; upper left), PG-LPS (L; upper right), PPL (P; lower right) and PG-LPS + PPL (L + P; lower right) groups. Scale bar = 50 μm. (B) The area of fibrosis was significantly increased in the L group (n = 5), but this increase was suppressed in the L + P group (n = 5). **P < 0 .01 by ANOVA/Tukey–Kramer. (C) Expression of α-SMA (normalized to GAPDH expression) as a marker of cardiac fibrosis was significantly increased in the P group (n = 7), but this increase was suppressed in the L + P group (n = 7). (D) Representative images of TUNEL-positive nuclei (black-brown) in TUNEL-stained sections of cardiac muscle. TUNEL-positive nuclei were counted in the Control (C; upper left), PG-LPS (L; upper right), PPL (P; lower left) and PG-LPS + PPL (L + P; lower right) groups. Scale bar = 20 μm. Black arrows: TUNEL-positive myocytes. (E) The number of TUNEL-positive nuclei was significantly increased in the L group (n = 4), but this increase was suppressed in the L + P group (n = 4). **P < 0.01 by ANOVA/Tukey–Kramer. (F) The Bax/Bcl-2 ratio, a parameter related to apoptosis, was significantly increased in the L group (n = 10), but this increase was suppressed in the L + P group (n = 9). **P < 0 .01 by ANOVA/Tukey–Kramer. Data are presented as means as means ± SD and dots show individual data. We also examined the level of α-SMA expression at 7 days after the start of PG-LPS because this parameter is closely associated with cardiac fibrosis 29,30, and confirmed that the data was in accordance with the Masson-trichrome staining (Fig. 4C). These data support the idea that cardiac fibrosis induced by PG-LPS infusion might be mediated, at least in part, through the activation of β-AR signaling. Effects of PG-LPS with/without PPL treatment on cardiac apoptosis We next assessed cardiac myocyte apoptosis in PG-LPS-treated mice with/without PPL treatment by means of terminal deoxyribonucleotidyl transferase (TdT)-mediated biotin-16-deoxyuridine triphosphate (dUTP) nick-end labelling (TUNEL) (Fig. 4D). Chronic PG-LPS treatment significantly increased cardiac myocyte apoptosis (Control [n = 5] vs. PG-LPS [n = 5]: 1.0 ± 0.2 vs. 5.1 ± 1.2%, P < 0.01 by ANOVA/Tukey–Kramer). PPL alone did not affect the number of TUNEL-positive cardiac myocytes, but it blocked the PG-LPS-induced increase of TUNEL-positive cardiac myocytes (PG-LPS [n = 5] vs. PG-LPS + PPL [n = 5]: 5.1 ± 1.2 vs. 1.8 ± 1.4%, P < 0.01 by ANOVA/Tukey–Kramer) (Fig. 4E). We also examined the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 protein (BCL-2) protein, a well-known apoptotic marker 31, in the heart of PG-LPS-treated mice with/without PPL, and confirmed that the results were in accordance with the TUNEL staining data (Fig. 4F). These data support the idea that the increase of TUNEL-positive cardiac myocytes induced by PG-LPS treatment might be mediated, at least in part, through the activation of β-AR signaling. Effects of PG-LPS with/without PPL treatment on oxidative stress We assessed oxidative stress in the myocardium by means of 8-hydroxy-2’-deoxyguanosine (8-OHdG) immunostaining (Fig. 5A). Effects of PPL on PG-LPS-induced oxidative stress in the heart. (A) Representative images of 8-OHdG-immunostained sections of cardiac muscle in the Control (C; upper left), PG-LPS (L; upper right), PPL (P; lower left) and PG-LPS + PPL (L + P; lower right) groups. Scale bar = 20 μm. Black arrows: 8-OHdG-positive myocytes. (B) The number of 8-OHdG-positive myocytes was significantly increased in the L group (n = 4), but this increase was suppressed in the L + P group (n = 4). **P < 0 .01 by ANOVA/Tukey–Kramer. (C) Expression of XO (normalized to GAPDH) was significantly increased in the L group (n = 10), but this increase was suppressed in the L + P group (n = 10). **P < 0 .01 by ANOVA/Tukey–Kramer. (D) Expression of NOX4 (normalized to GAPDH) was significantly increased in the L group (n = 10), but this increase was suppressed in the L + P group (n = 10). **P < 0 .01 by ANOVA/Tukey–Kramer. Data are presented as means ± SD and open circles show individual data. We first prepared positive and negative control sections by incubating cells with (positive control)/without (negative control) 0.3% H2O2 in TBS-T for 1 h at room temperature before the anti-8-OHdG antibody treatment and confirmed that the 8-OHdG staining procedure could readily identify 8-OHdG antibody-positive and non-positive nuclei (Supplementary Fig. 2). The ratio of 8-OHdG-positive/total cells was significantly increased in the PG-LPS group (Control [n = 5] vs. PG-LPS [n = 5]: 1.2 ± 0.16 vs. 7.2 ± 1.5%, P < 0.01 by ANOVA/Tukey–Kramer), and the increase was suppressed by PPL (PG-LPS [n = 5] vs. PG-LPS + PPL [n = 5]: 7.2 ± 1.5 vs. 1.2 ± 0.3%, P < 0.01 by ANOVA/Tukey–Kramer) (Fig. 5B). Effects of PG-LPS with/without PPL treatment on XO and NOX4 expression Sustained β-AR activation augments ROS production through a number of signaling pathways, including NOX and XO, and may be involved in apoptosis and cardiovascular degeneration 32,33. Xanthine oxidase (XO) and nicotinamide adenine dinucleotide phosphatase 4 (NOX4) are expressed in the heart, and their activity is regulated by their expression level 29,34. We therefore examined NOX4 and XO protein expression in the heart among the four groups. XO expression was significantly increased by PG-LPS treatment (Control [n = 10] vs. PG-LPS [n = 10]: 100 ± 30 vs. 144 ± 20%, P < 0.01 by ANOVA/Tukey–Kramer). This increase was significantly attenuated by PPL (PG-LPS [n = 10] vs. PG-LPS + PPL [n = 10]: 144 ± 20 vs. 89 ± 25%, P < 0.01 by ANOVA/Tukey–Kramer) (Fig. 5C). In addition, NOX4 expression was significantly increased by PG-LPS treatment (Control [n = 10] vs. PG-LPS [n = 10]: 100 ± 19 vs. 130 ± 24%, P < 0.01 by ANOVA/ Tukey–Kramer), and this increase was also attenuated by PPL (PG-LPS [n = 10] vs. PG-LPS + PPL [n = 10]: 130 ± 24 vs. 89 ± 14%, P < 0.01 by ANOVA/ Tukey–Kramer) (Fig. 5D). These data suggest that chronic PG-LPS treatment increased the generation of ROS derived from XO and NOX4 at least in part through the activation of β-AR signaling. Effects of PG-LPS with/without PPL treatment on RIP3 expression ROS derived from NOX4 is considered to cause apoptosis and necroptosis via activation of receptor-interacting protein 3 (RIP3), a key protein of necrosis, in cardiac myocytes (Fig. 6A) 35. We thus examined the amount of RIP3 in the heart in the four groups and found that it was significantly increased in the heart of PG-LPS-treated mice (Control [n = 10] vs. PG-LPS [n = 10]: 100 ± 23 vs. 150 ± 21%, P < 0.01 by ANOVA/Tukey–Kramer). Again, this increase was significantly attenuated by PPL (PG-LPS [n = 10] vs. PG-LPS + PPL [n = 10]: 150 ± 21 vs. 82 ± 35%, P < 0.01 by ANOVA/Tukey–Kramer) (Fig. 6A). Effects of PPL on RIP3, CaMKII, RyR2, PLB in the heart. (A) RIP3 expression (normalized to GAPDH) was significantly increased in the L group, and this increase was significantly attenuated in the L + P group. **P < 0 .01 by ANOVA/Tukey–Kramer. (B) CaMKII phosphorylation (Thr-286) was significantly increased in the L group, and this increase was significantly attenuated in the L + P group. **P < 0 .01 by ANOVA/Tukey–Kramer. (C) CaMKII oxidation (Met-281/282) was significantly increased in the L group, and this increase was significantly attenuated in the L + P group. **P < 0 .01 by ANOVA/Tukey–Kramer. (D) RyR2 phosphorylation (Ser-2814) was significantly increased in the L group, and this increase was significantly attenuated in the L + P group. *P < 0 .05, **P < 0 .01 by ANOVA/Tukey–Kramer. (E) PLB phosphorylation (Thr-17) was significantly increased in the L group, and this increase was significantly attenuated in the L + P group. **P < 0 .01 by ANOVA/Tukey–Kramer. (F) NLRP3 was significantly increased in the L group, and this increase was significantly attenuated in the L + P group. **P < 0 .01 by ANOVA/Tukey–Kramer. Bar plots represent means ± SD and open circles show individual data. These data suggest that chronic PG-LPS exposure might increase RIP3 expression, leading to increased apoptosis and necrosis through the activation of β-AR signaling. Effects of PG-LPS with/without PPL treatment on CaMKII activation RIP3, which is a key determinant of necroptosis, plays an important role in oxidative stress-triggered cardiac injury, thus leading to myocardial remodeling and heart failure 36. We thus examined the amounts of phospho-CaMKII (Thr-286) (Fig. 6B) and oxidized methionine-281/282 CaMKII (ox-CaMKII) (Fig. 6C) and found that they were significantly increased in the heart of PG-LPS-treated mice (CaMKII [Thr-286]: Control [n = 9] vs. PG-LPS [n = 10]: 100 ± 14 vs. 182 ± 21%, P < 0.01 by ANOVA/Tukey–Kramer; ox-CaMKII: Control [n = 10] vs. PG-LPS [n = 10]: 100 ± 25 vs. 154 ± 28%, P < 0.01 by ANOVA/Tukey–Kramer). These increases were significantly attenuated by PPL (CaMKII [Thr-286]: PG-LPS [n = 10] vs. PG-LPS + PPL [n = 8]: 182 ± 21 vs. 108 ± 47%, P < 0.01 by ANOVA/Tukey–Kramer; ox-CaMKII: PG-LPS [n = 10] vs. PG-LPS + PPL [n = 10]: 154 ± 28 vs. 97 ± 29%, P < 0.01 by ANOVA/Tukey–Kramer). These data suggest that chronic PG-LPS treatment might activate the RIP3/CaMKII signaling pathway through the activation of β-AR. Effects of PG-LPS with/without PPL on PLB phosphorylation Sustained, excessive CaMKII activation is an upstream signaling event leading to Ca2+-mishandling by proteins located in the sarcoendoplasmic reticulum (SR), including ryanodine receptor 2 (RyR2) and phospholamban (PLB), resulting in cardiac remodeling and dysfunction 37. We thus examined the effects of chronic PG-LPS on RyR2 phosphorylation at Ser-2814 (Fig. 6D) and PLB phosphorylation at Thr-17 (Fig. 6E) in the heart in the four groups; these phosphorylations are mediated by CaMKII 27. Both phosphorylations were significantly increased in the heart of PG-LPS-treated mice (phospho-RyR2 [Ser-2814]: Control [n = 8] vs. PG-LPS [n = 10]: 100 ± 21 vs. 135 ± 25%, P < 0.05 by ANOVA/Tukey–Kramer; phospho-PLB (Thr-17): Control [n = 8] vs. PG-LPS [n = 8]: 100 ± 26 vs. 173 ± 70%, P < 0.01 by ANOVA/Tukey–Kramer). These increases were significantly attenuated by PPL (phospho-RyR2 (Ser-2814): PG-LPS [n = 10] vs. PG-LPS + PPL [n = 10]: 135 ± 25 vs. 83 ± 27%, P < 0.01 by ANOVA/Tukey–Kramer; phospho-PLB (Thr-17): PG-LPS [n = 8] vs. PG-LPS + PPL [n = 8]: 173 ± 70 vs. 44 ± 39%, P < 0.01 by ANOVA/Tukey–Kramer). These data, together with previous findings 37, suggest that PG-LPS might increase the phosphorylation levels of RyR2 and PLB, at least in part, through the activation of the RIP3/CaMKII signaling pathway, leading to Ca2+-leakage in cardiac myocytes and cardiac dysfunction. Effects of PG-LPS on NLRP3 protein expression with/without PPL NOD-like receptor family, pyrin domain-3 (NLRP3) inflammasome is a multiprotein complex and functions as a sensor for cellular stress signals including oxidative stress and intracellular calcium leakage in various cells including myocytes 38. In addition, NLRP3 inflammasome is involved in the development of cardiac dysfunction in response to chronic catecholamine stress 39. We thus examined the expression of NLRP3 protein by western blotting. Protein expressions of NLRP3 was significantly increased in the BO-treated mice (Control [n = 5] vs. BO [n = 5]; 100 ± 24 vs. 235 ± 52%, P < 0.01 by ANOVA/Tukey–Kramer). The increase was suppressed by propranolol (PG-LPS [n = 5] vs. PG-LPS + propranolol [n = 5]; 235 ± 52 vs. 102 ± 28%, P < 0.01 by ANOVA/Tukey–Kramer) (Fig. 6F). These data, together with the results of previous studies, suggest that chronic PG-LPS treatment might activate the NLRP3 inflammasome pathway via increased ROS production and calcium leakage and thereby contribute to the development of cardiac dysfunction induced by PG-LPS. Discussion The major findings of this study were as follows. In mice treated with PG-LPS at a dose consistent with the circulating levels in periodontitis patients we found that: 1) nLF, which may reflect sympathetic activity, and LF/HF, which may reflect sympatho-vagal balance, were significantly increased. 2) nHF, a possible marker of parasympathetic activity was significantly decreased at all time points examined after the PG-LPS treatment. 3) SDNN, which may be a measure of total autonomic instability, was also significantly decreased at all time points. 4) Circadian rhythm of HR was diminished. 5) Chromogranin A and TH phosphorylation, which are considered to be parameters of sympathetic nervous activity, were significantly increased after the PG-LPS treatment. 6) Cardiac function was impaired. 7) Myocyte apoptosis, cardiac fibrosis and oxidative DNA damage in the myocardium were increased. 8) These changes after PG-LPS treatment were attenuated by pharmacological inhibition of β-AR with the non-selective β-blocker propranolol. These data suggest that PG-LPS treatment under the conditions used in this study might induce activation of β-AR signaling and thus indicate that PG-LPS might contribute, at least in part, to the development of CVD in patients with PD. We have recently demonstrated that persistent activation of toll-like receptor 4 (TLR4) with PG-LPS exacerbated cardiac dysfunction, as well as myocyte apoptosis and fibrosis in cardiac tissue in mice 20. Mice lacking TLR4 have a lower HR at baseline and an altered HR response to restraint stress, which results from an increase of parasympathetic activity 40. In addition, anti-TLR4 antibody treatment in adult hypertensive rats (spontaneously hypertensive rats) induces a decreased mean arterial pressure as well as a decreased contractile response in mesenteric arteries upon infusion of the endogenous β1-agonist noradrenaline 41. These data suggest that the interplay of TLR4 signaling and β1-AR signaling might contribute, at least in part, to the pathogenesis of cardiac dysfunction in mice treated with PG-LPS. We thus hypothesized that the non-selective β-blocker PPL might protect the heart from PG-LPS-induced cardiac dysfunction, and our present findings support this view. To our knowledge, this study is the first to examine the effects of PG-LPS on HR and HRV in mice. Mean HR was significantly increased in mice treated with PG-LPS at all examined time points after PG-LPS treatment. In addition, nLF, which may represent sympathetic nervous activity, was significantly greater than baseline, and nHF, which may represent parasympathetic activity, was significantly decreased from baseline at all time points after PG-LPS treatment. SDNN reflects the balance between the sympathetic and parasympathetic inputs to the cardiac pacemaker and thus SDNN is also a measure of total autonomic instability 23,42,43. Our previous studies in type 5 adenylyl cyclase (AC) knockout mice demonstrated that type 5 AC, a major cardiac and Gi-inhibitable AC isoform in adults, plays a major role in parasympathetic regulation of cardiac function in addition to sympathetic regulation 44. Increased HR after the PG-LPS treatment might be mediated at least in part through altered parasympathetic modulation via type 5 AC in addition to sympathetic nerve overactivity. We also examined the variation of HR (delta HR) from daytime to nighttime at baseline and at 7 days after PG-LPS treatment, and found that the difference was significantly greater at baseline, compared to 7 days after PG-LPS treatment. This indicates that the circadian rhythm of HR was diminished by PG-LPS. It is well established that disruption of the circadian rhythm of HR is linked to various diseases, including CVD 45–48. We thus anticipated that altered circadian rhythm of HR in mice treated with PG-LPS might play a part in the development of cardiac dysfunction. HRV analysis is a simple, non-invasive, and generally accepted tool for the evaluation of autonomic modulation of the cardiovascular system, making it possible to infer the seriousness of a cardiovascular disease and the success of a cardiovascular pharmacological treatment. However, like other tools, HRV analysis methods have limitations. HRV analysis (time or frequency domain method) does not provide a direct measurement of autonomic cardiac activity and does not provide a direct measurement of either cardiac sympathetic or parasympathetic activity. Thus, any relationship between HRV and cardiac autonomic regulation is qualitative rather than quantitative in nature 49. In other words, a low or high level of HRV may reflect decreased or increased cardiac autonomic regulation, respectively, but does not provide a quantitative measure of the actual cardiac nerve firing rate. Chromogranin A is a protein that is costored and coreleased by exocytosis with norepinephrine in sympathetic nerve endings 24,25 and norepinephrine synthesis is dependent on phosphorylation-induced changes in the activity of TH, which converts tyrosine to DOPA 26, the rate-limiting reaction in catecholamine synthesis. Thus, plasma chromogranin A and TH phosphorylation levels might be useful probe to validate the sympathetic activity. Therefore, to overcome the limitations of HRV analysis, we examined autonomic cardiac autonomic activity by measuring serum chromogranin A by ELISA (Fig. 3C) and cardiac tyrosine hydroxylase activity by western blotting (Fig. 3D). The results provide further evidence that the sympathetic nervous system was activated more in PG-LPS-mediated mice compared to the control. RIP3 is a key mediator of programmed necrosis (necroptosis), and is implicated in cardiac remodeling and heart failure triggered by oxidative stress through activation of CaMKII, which was alleviated by RIP3 depletion 36,50,51. Therefore, ROS derived from NOX4 and/or XO might activate RIP3/CaMKII signaling and induce cardiac myocyte apoptosis and necroptosis, leading to heart failure (Fig. 7) 35,52. Proposed role of β-AR signaling in the heart of PG-LPS-treated mice. β-AR/Gsα/AC signaling is activated by the PG-LPS treatment, leading to ROS production through XO and NOX4 and Ca2+ leakage, which mediates RyR2 phosphorylation at Ser-2814 and PLB phosphorylation at Thr-17 via activation of ROS/RIP3/CaMKII signaling. These changes might cause activation of NLRP3 inflammasome pathway, leading to fibrosis, myocyte apoptosis, oxidative stress and cardiac dysfunction. β-AR, β-adrenoreceptor; Gsα, α subunit of Gs; AC5, type 5 adenylyl cyclase; SERCA, sarcoendoplasmic reticulum ATPase; SR, sarcoendoplasmic reticulum; RyR2, ryanodine receptor 2; PLB, phsopholamban; NLRP3, NOD-like receptor family, pyrin domain-3. Increasing evidence suggests that persistent oral disease including periodontitis might contribute to systemic diseases including CVD, highlighting the importance of understanding their pathogenic mechanism 53. The Suita study, which consisted of a random sample of Japanese urban residents, demonstrated that oral health disorders such as periodontitis are significantly associated with increased risk of hypertension 54. However, the pathways that mediate systemic disease induced by periodontitis remains poorly understood. NLRP3 inflammasome, a multiprotein complex within the innate immune system is a key component in host defense 55. Although NLRP3 plays a crucial role in protecting the body from illness, excessive or uncontrolled activation of this protein can lead to tissue-injury and adverse health outcomes 56. Our findings here indicate that the NLRP3 inflamamsome pathway contributes, at least in part, to the development of CVD in patients with periodontitis (Fig. 7). In summary, the major findings of the current investigation, taken together with the previous studies, indicate that inhibition of β-AR by the non-selective β-blocker PPL ameliorates the development of PG-LPS-induced cardiac dysfunction by reducing. Limitation In the present study, we used only male mice as a model of periodontitis to examine the effects of propranolol on PG-LPS-mediated cardiac dysfunction in mice. Future work should examine whether there is a sex-difference, because estrogen might alter the β-AR distribution and function 57, oral health such as periodontitis prevalence 58 and heart rate variability 59. Methods Experimental protocol All experiments were performed on male 12-week-old C57BL/6 mice obtained from CLEA Japan (Tokyo, Japan). Mice were housed in groups at 23˚C under a 12/12-h lightin cycle (lights on at 8:00 AM, lights off at 8:00 PM) in line with the standard conditions for mouse studies by our group 31,60,61. Both food and water were available ad libitum. PG-LPS (#14,966–71; Invivogen, San Diego, CA, USA) was dissolved in saline to prepare a 0.6 mg/ml stock solution, and an appropriate volume of this solution to provide the desired dose (PG-LPS: 0.8 mg/kg) was added to 0.2 mL of saline to prepare the solution for intraperitoneal (i.p.) injection (once daily for 1 week) 62. Mice were housed in groups of approximately 3 per cage and were divided into four groups: a normal control group (Control), a PG-LPS treatment group (L), a PPL-only treatment group (P), and a PG-LPS plus PPL treatment group (L + P) (Fig. 1A). Propranolol-hydrochloride (#P0884; Sigma-Aldrich, St. Louis, MO, USA) was directly dissolved in drinking water (0.1 mg/mL; freshly prepared every day) 63,64. Mice were weight and monitored for food and water intake throughout the 1-week experimental period (C: n = 5, L: n = 5, P: n = 5, L + P: n = 5 each) (Fig. 1B). The dose of PG-LPS used in this study is compatible with the circulating levels in patients with periodontitis, indicating that this model is not a sepsis model, and indeed, no mortality was observed 65. After the completion of each treatment, mice were anesthetized with isoflurane (1.0–1.5% v/v) via a mask at room temperature and killed by cervical dislocation. The heart was quickly excised, rinsed thoroughly in phosphate-buffered saline to eliminate circulating blood in tissue, blotted on filter paper and weighed. The ratio of CM (mg) to BW (g) was used as an index of muscle growth (Fig. 1D). For the immunoblotting analysis, the excised heart tissue was immediately frozen in liquid nitrogen and stored at -80˚C until the preparation of crude protein homogenate. For the histologic analysis, the harvested heart tissue was immediately frozen in liquid nitrogen with Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA, USA) and stored at -80˚C until sectioning. Ethical approval All animal experiments complied with the ARRIVE (Animal Research Reporting in Vivo Experiments) guidelines 66 and were carried out in line with the National Institutes of Health guide for the care and use of laboratory animals 67 and institutional guidelines. The experimental protocol was approved by the Institutional Animal Care and Use Committee of Tsurumi University (No. 29A041). Telemetric ECG recording in mice Mice were anesthetized via a mask with isoflurane (1.0–1.5% v/v) at room temperature and then an abdominal midline incision was made on the vertical surface, and a telemetric transmitter (ATE-02S; Softron, Tokyo) was implanted at 14 days before the PG-LPS treatment (Fig. 2A). Mice were housed in individual cages with free access to food and water and were exposed to 12-h light/dark cycles (light, 8:00 AM to 8:00 PM; dark, 8:00 PM to 8:00 AM) in a thermostatically controlled room (23˚C). ECG data were recorded from the telemetric transmitter with the use of an under-cage receiver (ATR-1001; Softron, Tokyo) for 24 h at 1 day before the PG-LPS treatment to obtain the baseline and at 1, 3, 7 days after the PG-LPS treatment (Fig. 2A) 64. Measurement of circadian variation of HR for 24 h ECG signal processing was performed and HRV analysis was done with SRV2 software (Softron, Tokyo). This software detects R waves from all ECG leads after passing the signals through a filter that eliminates noise and applying an algorithm that detects ECG fiducial points. We calculated circadian variations of HR for 24 h at 1 day before and 7 days after PG-LPS treatment to examine the effects of PG-LPS on HR circadian variation. In addition, we calculated mean HR during daytime (8:00 AM to 8:00 PM) and nighttime (8:00 PM to 8:00 AM) to examine the circadian variation of HR between nighttime and daytime at 1 day before and 7 days after PG-LPS treatment. Measurement of HRV Conscious mice were kept in individual cages, which were placed on a receiver, and data from the freely moving mice were recorded by the data acquisition system 23. Time-domain analyses were obtained directly from original R-R intervals time series. In time-domain analysis, SDNN represents an index of total autonomic instability 23,42. Frequency domain analyses were obtained in the total power (TP; 0—0.4 Hz), very-low frequency (below 0.04 Hz), low-frequency (LF; 0.04—0.15 Hz), and high frequency (HF; 0.15–0.4 Hz) bands of the spectrum of HRV. nLF (= LF × 100/[TP-VLF]) reflects the sympathetic activity, nHF (= HF × 100/[TP-VLF]) reflects the parasympathetic activity, and LF/HF is an index of the sympatho-vagal balance 22,68. Measurement of plasma chromogranin A The plasma was separated from blood samples collected from heart of the control and PG-LPS-treated mice for 7 days under anesthesia. Blood sampling was done in the morning (9:00–10:00AM) and the procedure was completed within 30 s from the time of contact with the mouse. The separated plasma samples were frozen at -80 °C until measurement. The levels of plasma chromogranin A were determined using a Mouse Chromogranin A ELISA Kit (ab264631; Cambridge, UK) in accordance with the manufacturer’s instructions. Echocardiogram experiments Mice were anesthetized with isoflurane vapor (1.0–1.5% v/v) titrated to maintain the lightest anesthesia possible and echocardiographic measurements were performed by ultrasonography (TUS-A300, Toshiba, Tokyo, Japan) as used previously by us 27,30,31 and other groups 69. The dose of isoflurane used in this study is most widely used for echocardiography in mice because it is expected to cause little cardiac depression 69,70. All LV dimensions on echocardiography were evaluated as the average of four successive selected beats. HR was determined from the cardiac cycles recorded on the M-mode traces, using at least three successive beats. The other parameters were calculated from LV dimensions determined by M-mode echocardiography (Teichholz formula) 71: ●EDV = (7 × LVIDd3/1000) / (2.4 + (LVIDd/10)) and ESV = (7 × LVIDs3/1000) / (2.4 + (LVIDd/10)) (mL). EDV (mL): left ventricular end-diastolic volume. ESV (mL): left ventricular end-systolic volume. LVIDd (mm): left ventricular internal dimension at end-diastole. LVIDs (mm): left ventricular internal dimension at end-systole. ● Stroke volume (SV) = EDV- ESV (mL). ● left ventricular ejection fraction (LVEF) = 100 × SV / EDV (%). ● left ventricular fractional shortening (%FS) = 100 x (LVIDd—LVIDs) / LVIDd (%). All LV dimensions determined by the Teichholz formula in wild-type control (12-week-old C57BL/6 mice) shown in this study were in agreement with those in previous studies reported by us 20 and another group 72. Masson-trichrome-staining (evaluation of fibrosis) Cardiac tissue was frozen in liquid nitrogen and sectioned (10 µm each ; Control; n = 5, PG-LPS; n = 5, PPL; n = 5, PG-LPS + PPL; n = 5) with a cryostat (CM1900, Leica Microsystes, Nussloch, Germany) at -20 ˚C. The cryostat sections were air-dried and fixed with 4% paraformaldehyde (v/v) in 0.1 M phosphate-buffered saline (pH 7.5). Masson-trichrome staining was performed using the Accustatin Trichrome Stain Kit (#HT15-1KT; Sigma) 27. Cardiac fibrotic regions were quantified using image analysis software (Image J 1.45) to evaluate the percentage of blue-stained area of myocardial fibers in the Masson-trichrome Sects. 29. TUNEL-staining (Evaluation of apoptosis) Apoptosis was determined by terminal deoxyribonucleotidyl transferase (TdT)-mediated biotin-16-deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) staining using the Apoptosis in situ Detection Kit (#293–71,501; FUJIFILM Wako, Osaka, Japan). TUNEL-positive nuclei per field of view were measured by manual counting in six sections from each of the four groups (10 µm each ; Control; n = 5, PG-LPS; n = 5, PPL; n = 5, PG-LPS + PPL; n = 5) over a microscopic field of 20 x, averaged and expressed as the ratio of TUNEL-positive nuclei (%) in accordance with the standard procedure for TUNEL staining by our group 31,73. Limiting the counting of total nuclei and TUNEL-positive nuclei to areas with true cross sections of myocytes made it possible to selectively count only those nuclei that were clearly located within myocytes. Immunohistochemistry (evaluation of oxidative stress [8-OHdG]) Immunostaining for 8-hydroxy2’-deoxyguanosine (8-OHdG) was performed to assess oxidative DNA damage in the myocardium using the Vector M.O.M Immunodetection system (#PK-2200,Vector Laboratories, Inc. Burlingame, CA, USA) in accordance with the standard procedure for immunostaining for 8-OHdG by our group 30,73. The cryostat Sects. (10 µm each ; Control; n = 5, PG-LPS; n = 5, PPL; n = 5, PG-LPS + PPL; n = 5) were air-dried and fixed with 4% paraformaldehyde (v/v) in TBS-T for 5 min at room temperature. Antigen retrieval was achieved with 0.1% citrate plus 1% Triton X-100 for 30 min at room temperature, then the sections were washed with TBS-T, incubated with 0.3% horse serum in TBS-T for 1 h at room temperature, and blocked with M.O.M. blocking reagents (Vector Laboratories, Burlingame, CA, USA) overnight at 4˚C. For the positive control, sections were incubated with 0.3% H2O2 in TBS-T before the anti-8-OHdG antibody treatment. The sections were incubated with anti-8-OHdG antibody (8.3 μg/ml in M.O.M. Dilute; clone N45.1 monoclonal antibody; Japan Institute for the Control of Aging, Shizuoka, Japan) overnight at 4˚C in a humidified chamber, and then incubated with 0.3% H2O2 in 0.3% horse serum for 1 h at room temperature to inactivate endogenous peroxidase, rinsed with TBS-T, incubated with anti-mouse IgG in M.O.M. Diluent, and processed with an ABC kit (Vector Laboratories Burlingame, CA, USA). The ratio of 8-OHdG nuclei with oxidative DNA damage (stained dark brown) per total cell number was measured by manual counting. Western blotting The cardiac muscle excised from the mice was homogenized in a Polytron (Kinematica AG, Lucerne, Switzerland) in ice-cold RIPA buffer (Thermo Fisher Scientific, Waltham, MA, USA: 25 mM Tris–HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodiumdeoxycholate, 0.1% SDS) with addition of Halt™ Protease Inhibitor Cocktail, EDTA-free (#87,785; ThermoFisher Scientific). The homogenate was centrifuged at 13,000 × g for 10 min at 4˚C. The supernatant was collected and the protein concentration was measured using a DC protein assay kit (Bio-Rad, Hercules, CA, USA). Equal amounts of protein (5 μg) were separated on 4–20% SDS–polyacrylamide gel, transferred to a nitrocellulose membrane (#IPVH00010, Immobilon®-P PVDF membrane, Merck Millipore, Burlington, MA, USA) and incubated overnight with a primary antibody 60,73,74. The primary antibodies against α-smooth muscle actin (α-SMA) (1:1000, #19,245), CaMKII (1:1000,#3362), phospho-CaMKII (1:1000, Thr-286, #3361), BAX (1:1000, #2772),BCL-2(1:1000, # 3498) and RIP3 (1:1000, #2058), phospho-TH (1:1000, Ser-40, #2791) and TH (1:1000, #58,844), and NLRP3 (1:1000, #15,100) were purchased from Cell Signaling Technology (Boston, MA, USA), the primary antibodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:200, sc-32233) wss purchased from Santa Cruz Biotechnology (SantaCruz, CA, USA), the primary antibodies against phospho-phospholamban (PLB) (1:5000, Thr-17, #A010-13) phospho-RyR2 (1:5000) (Ser-2814, A010-31), and PLB (1:5000, #A010-14), were purchased from Badrilla (Leeds,UK), and the primary antibodies against NOX4 (1:1000, #ab133303) and XO (1:1000, #ab109235) were purchased from Abcam (Cambridge, UK). The primary antibodies against oxidized CaMKII (Met-281/282) (1:1000, 071,387) were purchased from Merck (San Jose, CA, USA). And RyR2 (1:1000, #MA3–916) was purchased from Thermo Fisher (Rockland, IL, USA). Horseradish peroxide-conjugated anti-rabbit (1:5000, #NA934) or anti-mouse IgG (1:5000, #NA931) (GB Healthcare, Piscataway, NJ, USA) was used as a secondary antibody. The primary and secondary antibodies were diluted in Tris-buffered saline (pH 7.6) with 0.1% Tween 20 and 5% bovine serum albumin or immunoreaction enhancer solution (Can Get Signal; TOYOBO, #NKB-101, Osaka, Japan). The blots were visualized with enhanced chemiluminescence solution (ECL: Prime Western Blotting Detection Reagent, GE Healthcare) and scanned with a densitometer (ASL-600, GE Healthcare). Images of full-size immunoblots are shown in Supplementary Material 2 (original images). Statistical analysis Data are expressed as means ± SD. Comparison of data was performed using a one-way repeated-measures analysis of variance (ANOVA) followed by the Bonferroni post hoc test (Figs. 2B-F), student’s paired t-test (Fig. 3A) and student’s unpaired t-test (Fig. 3B-D) when compared between 2 groups, or one-way ANOVA followed by the Tukey–Kramer post hoc test for 3 or more groups (Fig. 1B-D, 4B, C, E, F, 5B-D and 6A-F, Table 1). The criterion of significance was taken as P < 0.05. We calculated the required total sample size of animals (α risk = 0.05, power (1-β) = 0.8) not only a priori (effect size (f) = 0.4) but also a posterior with the effects size (f) derived from post hoc 29 by means of G* Power version 3.1 (program, concept and design by Franz, Universitat Kiel, Germany; freely available Windows application software) (Supplementary Material 3). Supplementary Information Below is the link to the electronic supplementary material. Supplementary Information. Supplementary Information. Supplementary Information. Acknowledgements We would like to thank Richard Steele for English language editing. Images in Figure 1 and Figure 7 were created with BioRender (https://biorender.com/). Author contributions I.M.: almost all experiments, formal analysis, writing and funding acquisition. K.S.: echocardiographic experiments and funding acquisition. Y.O.: HRV analysis and funding acquisition. M.I.: histological experiments. A.I., methodology and funding acquisition. M.A.: methodology. T.M.: implantation of telemetry transmitter and acquisition of HR data. Y.M.: statistical analysis and validation. R.M.: implantation of telemetry transmitter and animal care. M.N.: statistical analysis and funding acquisition. T.N.: methodology. Y.H.: histological experiments and funding acquisition. D.C.: supervision. A.M.: supervision and funding acquisition. S.O.: conceptualization, reviewing, editing and funding acquisition. All authors have read and approved the final manuscript. Funding This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant (24K20123 to IM, 23K09493, 26K13010 to KS, 23K09517, 26K12988 to YO, 24K20067 to AI, 25K13259 to MN, 25K20491 to YH, 25K13345 to AM and 24K13250 to SO) and Mitsui Sumitomo Public Trust Cardiovascular Research Fund (2022) (to IM). The founders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Data availability The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Information. Supplementary Information. Supplementary Information. Data Availability Statement The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.